2. Vías de señalización
  3. GPCR/G Protein
    Immunology/Inflammation
  4. CXCR
  5. CXCR6 Isoform

CXCR6

CXCR6 is a class A GPCR that binds CXCL16, mediating leukocyte adhesion through transmembrane CXCL16 and migration through soluble CXCL16[1]. Mechanistically, the CXCL16/CXCR6 axis activates Akt, MAPK, and context-specific inflammatory programs in epithelial, immune, and tumor models[2][3]. In intestinal inflammation, CXCR6-expressing cells respond to CXCL16, and CXCL16 expression increases in Crohn’s disease tissues and inflammatory mouse models[2]. In liver injury models, CXCR6-dependent hepatic NKT cell accumulation promotes inflammatory cytokine production and liver fibrosis[4]. In CNS viral recovery, CXCL16/CXCR6 maintains CD8+ tissue-resident T cells, glial activation, and ongoing synapse elimination[5]. Compared with related chemokine receptors, CXCR6 carries a DRF motif rather than the typical DRY motif, supporting adhesion and cell retention while reducing chemotactic response[1]. For experimental applications, CXCR6 blockade or CXCL16 targeting can test tissue-resident T-cell maintenance, inflammatory recruitment, fibrosis progression, and tumor-immune interactions[4][5][6].

Productos relacionados con CXCR6 (2):

Cat. No. Nombre del producto Efecto Pureza
  • HY-122197
    ML339
    		Antagonist 99.88%
    ML339 is a selective CXCR6 antagonist with an IC50 of 140 nM. ML339 antagonizes β-arrestin recruitment and cAMP signaling pathway of human CXCR6 receptor induced by CXCL16, with IC50 of 0.3 μM and 1.4 μM, respectively. ML339 shows weaker activity against the recruitment of β-arrestin in mouse CXCR6 receptors, with an IC50 of 18 μM. ML339 has no inhibitory effect on CXCR5，CXCR4，CXCR6 and apelin receptor (APJ), with IC50 >79 μM. ML339 has the potential to promote the development of prostate cancer research.
  • HY-133151
    CXCR6 antagonist 1
    		Antagonist
    CXCR6 antagonist 1 (Compound 81) is an orally active CXCR6 antagonist. CXCR6 antagonist 1 inhibits the CXCR6 receptor signaling pathway, including β-arrestin recruitment and Forskolin (HY-15371)-induced cAMP production. CXCR6 antagonist 1 reduces tumor growth in a mouse xenograft model of hepatocellular carcinoma. CXCR6 antagonist 1 can be used in research related to hepatocellular carcinoma.